Two preparations, agalsidase alfa (Replagal®, Takeda) and agalsidase beta (Fabrazyme®, Sanofi), have been shown to slow disease progression when administered regularly and have been approved for the treatment of Fabry disease. This evidence concerns the gene GLA and Fabry disease.